The CDAI was developed based on its combined effect on anti-inflammatory effects based on the pro-inflammatory markers Tumor Necrosis Factor-α (TNF-α) and Interleukin-1β (IL-1β), which are associated with many health outcomes, including depression, all-cause mortality, colorectal cancer, etc. (21–25). The gene discussed is IL1B; the disease is depressive disorder.